Biotech Values

[Summer2762]

But their preliminary HR on OS is still very good. Maybe the crossover won't make such a difference because these patients just don't have much time after confirmed progression.

My fear is that HR=0.47 but no statistical significance and no verbiage of "strongly trending" means that not many OS events might have occurred. Since the trial is successful, I assumed all patients with or without PD will be able to crossover (I am not actually sure of this anymore), we might get a higher final HR and still no statistical significance.

I do not question the data and importance of this data for the NSCLC (or CRC) trial. I am not just sure what other investors will do if/when they encounter HR>0.47 at ASCO.